Press release
Spleen Tyrosine Kinase (Syk) Inhibitor Therapeutics Clinical Trials & Results | Levolta Pharmaceuticals, Inc., Rigel Pharmaceuticals Inc., Chi-Med (Hutchison China MediTech), Genosco Inc, Asana BioSciences, LLC
Download the sample report @ https://www.pharmaproff.com/request-sample/1198
Syk protein facilitates the phosphorylation of protein on tyrosines and also involves in the B cell antigen receptor (BCR) signalling pathways. There are several drugs that effectively inhibit the Syk kinase but the off-target effect is a limiting factor. Currently, there are various Syk inhibitors that prevent release of inflammatory cytokines in vitro and IgE-driven mast cell degranulation.
Get the detailed analysis @ https://www.pharmaproff.com/report/spleen-tyrosine-kinase-inhibitor
Levolta Pharmaceuticals Inc. is developing a drug candidate, that acts as Syk inhibitor for the treatment of immunological diseases. Rigel Pharmaceuticals Inc. is developing fostamatinib as a Syk inhibitor for the treatment of chronic immune thrombocytopenia and autoimmune hemolytic anemia. Hutchison China MediTech Limited is also developing HMPL-523 as a Syk inhibitor for the treatment of cancer indications. Some of the companies having pipeline of Syk inhibitor include Genosco Inc., Asana BioSciences LLC, and others.
Make enquiry before purchase @ https://www.pharmaproff.com/enquiry/1198
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.
Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com
About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Spleen Tyrosine Kinase (Syk) Inhibitor Therapeutics Clinical Trials & Results | Levolta Pharmaceuticals, Inc., Rigel Pharmaceuticals Inc., Chi-Med (Hutchison China MediTech), Genosco Inc, Asana BioSciences, LLC here
News-ID: 1772719 • Views: …
More Releases from Pharma Proff
Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates.
IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to…
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates.
Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete…
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome.
Download the sample report at: https://www.pharmaproff.com/request-sample/1189
Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in…
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances…
More Releases for Syk
Investigation announced for Long-Term Investors in shares of Stryker Corporation …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Stryker Corporation.
Investors who purchased shares of Stryker Corporation (NYSE: SYK) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Stryker officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.
On April 6,…
Investigation announced for Investors in shares of Stryker Corporation (NYSE: SY …
An investigation was announced concerning potential securities laws violations by Stryker Corporation in connection with certain financial statements.
Investors who purchased shares of Stryker Corporation (NYSE: SYK), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Stryker Corporation regarding its business, its prospects and its operations were materially false and…
Tyrosine Protein Kinase SYK Market Trends, Size, Competitive Analysis and Foreca …
The global tyrosine protein kinase SYK market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Tyrosine protein kinase SYK is also known as spleen tyrosine kinase (SYK). It is a non-receptor cytoplasmic enzyme and is primarily expressed in cells of hematopoietic lineage. It contains two adjacent SH2 domains that bind to immunoreceptor tyrosine-based activation motifs (ITAMs) to activate the enzyme. The major factor driving the…
Orthopedic Surgical Robots Market 2019 Key Trend, Future Opportunities Forecast …
Orthopedic surgical robots refer to the man-made robots that are specially designed to assist surgeons during orthopedic surgeries. Ever since the launch of these specialized robots and constant innovations, the orthopedic surgeries, surgeons, as well as the patients have been benefitting in terms of better outcomes, improved assistance, and approval of patients for surgery, respectively. FDA approved first robot for surgery in 2000 after which several complex surgeries were performed…
Global Tyrosine Protein Kinase SYK Market Research 2019
In this report, we analyze the Tyrosine Protein Kinase SYK Market from two aspects. One part is about its production and the other part is about its consumption. In terms of its production, we analyze the production, revenue, gross margin of its main manufacturers and the unit price that they offer in different regions from 2014 to 2019. In terms of its consumption, we analyze the consumption volume, consumption value,…
Spleen Tyrosine Kinase (Syk) Inhibitor Therapeutics-Pipeline Analysis 2018
Spleen tyrosine kinase (Syk) is a protein that belongs to the family of tyrosine kinases with an ability to initiate the inflammatory responses, by connecting immune cell receptors to intracellular signaling pathways. Therefore, Syk is an attractive target for improving the symptoms related to acute and chronic inflammation. In addition, the role of protein is recognized as a promoter in various types of cancers ranging from leukemia to retinoblastoma.
Download…
